|
|
|
05.12.25 - 17:18
|
Carisma Announces Delisting from Nasdaq and SEC Deregistration (PR Newswire)
|
|
|
PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC......
|
|
|
25.11.25 - 21:39
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 25.11.2025 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 25.11.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.11.2025
ISIN Name
CA04364G1063 ASCOT RES LTD
DE0006204589 MVISE AG O.N.
DE000A3EX3G0 GORE GERM.OFF.R.E. NA ON
GB00BK964W87 ASTRID INTELLI. LS -,0001
IM00BYYPQX37 KR1 PLC LS -,0019
US14216R1014 CARISMA THERAPEUTICS INC.
US40251W5076 GULF RES INC. O.N.
US62526P8775 BOLLINGER INNOV. INC....
|
|
|
|
|
|
|
|
|
|
|
|
|
10.07.25 - 23:33
|
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight (PR Newswire)
|
|
|
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory approvals. Key companies Bayer, Carisma Therapeutics, Moderna, Eureka Therapeutics,......
|
|
|
|
|
|
|
23.06.25 - 14:31
|
XFRA: W2J: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CARISMA THERAPEUTICS INC. W2J US14216R1014
AB/FROM ONWARDS 23.06.2025 14:23 CET...
|
|
|
|
|
23.06.25 - 13:39
|
XFRA: W2J: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CARISMA THERAPEUTICS INC. W2J US14216R1014 BAW/UFN...
|
|
|
23.06.25 - 13:33
|
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire EN)
|
|
|
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix's NeoCart® technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart®....
|
|
|
31.03.25 - 22:33
|
Carisma Therapeutics Provides Corporate Updates (PR Newswire)
|
|
|
Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
